Catalyst
Slingshot members are tracking this event:
Phase 2 Open-Label Extension Study of EN3835 in the Treatment of Cellulite expected to be complete in June 2018
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ENDP | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 18, 2018
Occurred Source:
https://clinicaltrials.gov/ct2/show/NCT02942160?term=endo+pharmaceuticals&draw=2
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Edematous Fibrosclerotic Panniculopathy, Cellulite
